Rhupus综合征的临床特点

doi:10.19723/j.issn.1671-167X.2021.05.020

Abstract

Abstract:

Objective: To investigate the clinical and serological features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) overlap syndrome (Rhupus syndrome). Methods: We retrospectively reviewed the medical records of 21 patients with Rhupus syndrome who were hospitalized at Department of Rheumatology and Immunology, People’s Hospital of Xinjiang Uygur Autonomous Region between January 2010 and January 2018. We compared the joint involvement, autoantibodies and clinical manifestations of Rhupus syndrome with 81 cases of RA-alone and 51 cases of SLE-alone. Results: In 21 patients with Rhupus syndrome, there are 3 males and 18 females. Compared with the SLE-alone group, the patients with Rhupus syndrome were older [(49.43±11.66) vs. (40.59±12.73), P=0.008]. The median age of the patients with Rhupus syndrome at RA onset was significantly younger than that of the RA-alone patients [(32.58±11.14) vs. (43.11±11.83), P=0.010]. Of the 21 patients with Rhupus syndrome, the initial diagnosis was RA in 57% (12/21), except 2 male patients, the other 10 patients with SLE manifestations were menopause, the mean age of amenorrhea or menopause was (44.30±5.33) (36-50) years. The mean interval between the onset of SLE and RA was 10.83 years. Two patients started with SLE manifestations. Moreover, both diseases simultaneously developed in 33.3% of the patients. Except one male patient, 3 patients were in menopause stage when RA and SLE appeared. The positive rate of specific antibody Rhupus syndrome was similar to that of RA. Renal damage was relatively rare in SLE related manifestations, but the incidence of interstitial lung disease was higher. There were no significant differences in the prevalence of complements C3 and C4, antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-SSA or anti-SSB antibody between the Rhupus syndrome and SLE-alone group. Conclusion: Rhupus syndrome is an overlapping syndrome in which RA and SLE coexist. Most of the diseases occur in RA and the related manifestations of RA are more serious than those of SLE. The incidence of Rhupus syndrome may be related to the change of sex hormone levels.

Key words: Arthritis, rheumatoid, Lupus Erythematosus, systemic, Rhupus syndrome

CLC Number:

R593.2

Zheng-fang LI,Xue WU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Yan ZHONG,Xiao-mei CHEN,Xin-yan MENG. Clinical features of patients with Rhupus syndrome[J].Journal of Peking University (Health Sciences), 2021, 53(5): 933-937.

Figures/Tables 3

Table 1

Demographic characteristics of three groups of patients"

Items	Rhupus syndrome (n=21)	RA-alone (n=81)	SLE-alone (n=51)
Age/years, $x ?$ ±s	49.43±11.66	52.21±10.96	40.59±12.73^*
Female/%	85.7	84.0	96.1
Age at SLE onset/years, $x ?$ ±s	25.56±6.36		33.71±12.94
Age at RA onset/years, $x ?$ ±s	32.58±11.14	43.11±11.83^*
Duration of SLE/years, $x ?$ ±s	4.00±1.41		6.92±6.15
Duration of RA/years, $x ?$ ±s	10.83±8.44	8.94±7.47

Table 1

Table 2

Table 3

References 19

[1]	Amezcua-Guerra LM, Springall R, Marquez-Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with “Rhupus”: A cross-sectional study [J]. Arthritis Res Ther, 2006, 8(5):R144. doi: 10.1186/ar2036
[2]	Toone EC Jr, Irby R, Pierce EL. The L.E. cell in rheumatoid arthritis [J]. Am J Med Sci, 1960, 240(5):599-608.
[3]	Schur PH. Systemic lupus erythematosus [M]//Beeson PB, McDermott W. Cecil-loeb textbook of medicine. 13th ed. Philadelphia, PA: WB Saunders, 1971: 821.
[4]	Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis [J]. Arthritis Rheum, 1988, 31(3):315-324. doi: 10.1002/(ISSN)1529-0131
[5]	Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40(9):1725.
[6]	Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited [J]. J Am Soc Nephrol, 2004, 15(2):241-250. pmid: 14747370
[7]	穆荣, 叶华, 陈适, 等. Rhupus综合征的回顾性临床分析 [J]. 中华内科杂志, 2006, 45(7):540-543.
[8]	Hayakawa S, Komine-Aizawa S, Osaka S, et al. Rembrandt’s Maria Bockenolle has a butterfly rash and digital deformities: Overlapping syndrome of rheumatoid arthritis and systemic lupus erythematosus [J]. Med Hypotheses, 2007, 68(4):906-909. pmid: 17113236
[9]	Fernandez A, Quintana G, Matteson EL, et al. Lupus arthropathy: Historical evolution from deforming arthritis to rhupus [J]. Clin Rheumatol, 2004, 23(6):523-526. doi: 10.1007/s10067-004-0951-2
[10]	Simon JA, Granados J, Cabiedes J, et al. Clinical and immunogenetic characterization of Mexican patients with “Rhupus” [J]. Lupus, 2002, 11(5):287-292. doi: 10.1191/0961203302lu189oa
[11]	Tani C, D’Aniello D, Sedie AD, et al. Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients [J]. Autoimmun Rev, 2013, 12(4):537-541. doi: 10.1016/j.autrev.2012.09.004 pmid: 23063507
[12]	Liu T, Li G, Mu R, et al. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: A single-centre study of 51 patients [J]. Lupus, 2014, 23(9):958-963. doi: 10.1177/0961203314526439 pmid: 24608963
[13]	Li J, Wu H, Huang X, et al. Clinical analysis of 56 patients with rhupus syndrome: Manifestations and comparisons with systemic lupus erythematosus: A retrospective case-control study [J]. Me-dicine, 2014, 93(10):e49.
[14]	Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment [J]. Semin Arthritis Rheum, 2017, 47(1):53-64. doi: 10.1016/j.semarthrit.2017.03.022
[15]	Sundaramurthy SA, Karsevar MP, van Vollenhoven RV. Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis [J]. J Clin Rheumatol, 1999, 5(1):9-16. pmid: 19078342
[16]	Piga M, Gabba A, Cauli A, et al. Rituximab treatment for “rhupus syndrome”: Clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study [J]. Lupus, 2013, 22(6):624-628. doi: 10.1177/0961203313482741 pmid: 23559669
[17]	Ikeda K, Sanayama Y, Makita S, et al. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus [J]. Clin Dev Immunol, 2013, 2013:697525.
[18]	Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes [J]. Autoimmun Rev, 2013, 12(3):363-373. doi: 10.1016/j.autrev.2012.06.004 pmid: 22743033
[19]	Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: An open-label study of 15 patients [J]. RMD Open, 2017, 3(2):e000555. doi: 10.1136/rmdopen-2017-000555

Related Articles 15

[1]	Jia-yi TIAN,Xia ZHANG,Gong CHENG,Qing-hong LIU,Shi-yang WANG,Jing HE. Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1083-1087.
[2]	Zhi-bo SONG,Yan GENG,Xue-rong DENG,Xiao-hui ZHANG,Zhuo-li ZHANG. Benefit of ultrasound in the phenotype recognition of psoriatic arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1061-1066.
[3]	Lu ZHANG,Xiao-hong HU,Cheng CHEN,Yue-ming CAI,Qing-wen WANG,Jin-xia ZHAO. Analysis of cervical instability and clinical characteristics in treatment-naive rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1049-1054.
[4]	Xue-rong DENG,Xiao-ying SUN,Zhuo-li ZHANG. Agreement between ultrasound-detected inflammation and clinical signs in ankles and feet joints in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1037-1042.
[5]	Liang LUO,Wen-gang HUO,Qin ZHANG,Chun LI. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036.
[6]	Hua ZHONG,Li-ling XU,Ming-xin BAI,Yin SU. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031.
[7]	Xue LOU,Li LIAO,Xing-jun LI,Nan WANG,Shuang LIU,Ruo-mei CUI,Jian XU. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025.
[8]	Jian-mei ZOU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Xue WU. Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 938-941.
[9]	Hao WU,Li-ping PAN,Heng LIU,Hong-bin WANG,Tai-guo NING,Yong-ping CAO. Effect of posterior tibial slope on the short-term outcome in mobile-bearing unicompartmental knee arthroplasty [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 877-882.
[10]	Cheng WANG,Ling-yu MENG,Na-yun CHEN,Dai LI,Jian-quan WANG,Ying-fang AO. Management algorithm for septic arthritis after anterior cruciate ligament reconstruction [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 850-856.
[11]	WANG Gui-hong,ZUO Ting,LI Ran,ZUO Zheng-cai. Effect of rebamipide on the acute gouty arthritis in rats induced by monosodium urate crystals [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 716-720.
[12]	MA Xiang-bo,ZHANG Xue-wu,JIA Ru-lin,GAO Ying,LIU Hong-jiang,LIU Yu-fang,LI Ying-ni. Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 721-727.
[13]	WU Jun-hui,CHEN Hong-bo,WU Yi-qun,WU Yao,WANG Zi-jing,WU Tao,WANG Meng-ying,WANG Si-yue,WANG Xiao-wen,WANG Jia-ting,YU Huan,HU Yong-hua. Prevalence and risk factors of osteoarthritis in patients with type 2 diabetes in Beijing, China from 2015 to 2017 [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 518-522.
[14]	ZHAO Kai,CHANG Zhi-fang,WANG Zhi-hua,PANG Chun-yan,WANG Yong-fu. Therapeutic effect of gene silencing peptidyl arginine deaminase 4 on pulmonary interstitial lesions induced by collagen-induced arthritis mice [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 235-239.
[15]	CAO Di,WANG Yan,WANG Liu-qing,SUN Xiao-lin,HUANG Fei,MENG Yang,REN Li-li,ZHANG Xue-wu. Expression of plasma Dickkopf-1 in patients with rheumatoid arthritis and its correlation with peripheral blood T cell subsets [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 255-260.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2]	. [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3]	. [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4]	. [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5]	. [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 351 -354 .

Items	Rhupus syndrome (n=21)	RA-alone (n=81)
Clinical features, n(%)
Morning stiffness	18 (85.7)	56 (69.1)
Polyarthritis	20 (95.2)	77 (95.1)
Rheumatoid nodule	1 (4.7)	8 (9.9)
Laboratory features, n(%)
RF	19 (90.5)	68 (84.0)
Anti-CCP	14 (66.7)	75 (92.6)^*
AKA	7 (33.3)	27 (33.3)
APF	8 (38.1)	11 (13.6)^*
Erosions on radiography, n(%)	20 (95.2)	65 (80.2)

Items	Rhupus syndrome (n=21)	SLE-alone (n=51)
Clinical features, n(%)
Malar or discoid lupus	5 (23.8)	28 (54.9)^*
Oral ulcers	3 (14.2)	11 (21.6)
Raynaud’s phenomena	5 (23.8)	8 (15.6)
Renal disorder (proteinuria)	5 (23.8)	26 (50.9)^*
Interstitial pulmonary diseases	10 (47.6)	5 (9.8)^△
Haematological disorder	12 (57.1)	25 (49.0)
Laboratory features, n(%)
ESR	21 (100.0)	39 (76.4)^*
CRP	16 (76.2)	20 (39.2)^#
Decreased complement C3	16 (76.2)	37 (72.5)
Decreased complement C4	16 (76.2)	43 (84.3)
Anti-dsDNA	9 (42.8)	34 (66.7)
SSA	12 (57.1)	34 (66.7)
SSB	2 (9.5)	11 (21.6)
RF	19 (90.5)	8 (15.6)^△
Anti-CCP	14 (66.7)	0^△

Clinical features of patients with Rhupus syndrome

RICH HTML

PDF (PC)